CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
2010
122
LTM Revenue $112M
LTM EBITDA -$11.1M
-$41.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CytomX Therapeutics has a last 12-month revenue of $112M and a last 12-month EBITDA of -$11.1M.
In the most recent fiscal year, CytomX Therapeutics achieved revenue of $101M and an EBITDA of -$4.3M.
CytomX Therapeutics expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See CytomX Therapeutics valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $53.2M | $101M | $116M | $112M | XXX |
Gross Profit | n/a | n/a | n/a | XXX | XXX |
Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
EBITDA | -$98.9M | -$4.3M | -$6.4M | -$11.1M | XXX |
EBITDA Margin | -186% | -4% | -6% | -10% | XXX |
Net Profit | -$83.6M | -$99.3M | -$0.6M | XXX | XXX |
Net Margin | -157% | -98% | 0% | XXX | XXX |
Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 10, 2025, CytomX Therapeutics's stock price is $1.
CytomX Therapeutics has current market cap of $65.7M, and EV of -$41.3M.
See CytomX Therapeutics trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
-$41.3M | $65.7M | XXX | XXX | XXX | XXX | $-0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 10, 2025, CytomX Therapeutics has market cap of $65.7M and EV of -$41.3M.
CytomX Therapeutics's trades at -0.4x LTM EV/Revenue multiple, and 3.7x LTM EBITDA.
Analysts estimate CytomX Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for CytomX Therapeutics and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | -$41.3M | XXX | XXX | XXX |
EV/Revenue | -0.4x | XXX | XXX | XXX |
EV/EBITDA | 6.4x | XXX | XXX | XXX |
P/E | -16.3x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | 0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCytomX Therapeutics's NTM/LTM revenue growth is -32%
CytomX Therapeutics's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, CytomX Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate CytomX Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for CytomX Therapeutics and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 14% | XXX | XXX | XXX | XXX |
EBITDA Margin | -6% | XXX | XXX | XXX | XXX |
EBITDA Growth | 49% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | -38% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 30% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 77% | XXX | XXX | XXX | XXX |
Opex to Revenue | 106% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CytomX Therapeutics acquired XXX companies to date.
Last acquisition by CytomX Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . CytomX Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was CytomX Therapeutics founded? | CytomX Therapeutics was founded in 2010. |
Where is CytomX Therapeutics headquartered? | CytomX Therapeutics is headquartered in United States of America. |
How many employees does CytomX Therapeutics have? | As of today, CytomX Therapeutics has 122 employees. |
Who is the CEO of CytomX Therapeutics? | CytomX Therapeutics's CEO is Dr. Sean A. McCarthy, D.Phil.. |
Is CytomX Therapeutics publicy listed? | Yes, CytomX Therapeutics is a public company listed on NAS. |
What is the stock symbol of CytomX Therapeutics? | CytomX Therapeutics trades under CTMX ticker. |
When did CytomX Therapeutics go public? | CytomX Therapeutics went public in 2015. |
Who are competitors of CytomX Therapeutics? | Similar companies to CytomX Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of CytomX Therapeutics? | CytomX Therapeutics's current market cap is $65.7M |
What is the current revenue of CytomX Therapeutics? | CytomX Therapeutics's last 12-month revenue is $112M. |
What is the current EBITDA of CytomX Therapeutics? | CytomX Therapeutics's last 12-month EBITDA is -$11.1M. |
What is the current EV/Revenue multiple of CytomX Therapeutics? | Current revenue multiple of CytomX Therapeutics is -0.4x. |
What is the current EV/EBITDA multiple of CytomX Therapeutics? | Current EBITDA multiple of CytomX Therapeutics is 3.7x. |
What is the current revenue growth of CytomX Therapeutics? | CytomX Therapeutics revenue growth between 2023 and 2024 was 14%. |
Is CytomX Therapeutics profitable? | Yes, CytomX Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.